News
MEDP
340.18
-0.65%
-2.24
Medpace Holdings, Inc. Just Recorded A 5.6% EPS Beat: Here's What Analysts Are Forecasting Next
Simply Wall St · 20h ago
Medpace Holdings: Strong Q4 Performance and Financial Health Justify Buy Rating Despite 2025 Challenges
TipRanks · 1d ago
Medpace price target lowered to $358 from $362 at Baird
TipRanks · 2d ago
Medpace Holdings Full Year 2024 Earnings: EPS Beats Expectations
Simply Wall St · 2d ago
Medpace Reports Revenue and Income Growth in 2024
TipRanks · 3d ago
Medpace Holdings, Inc. and Subsidiaries Annual Report on Form 10-K for Fiscal Year Ended December 31, 2024
Press release · 3d ago
Medpace Holdings: Navigating Growth and Challenges in 2025
TipRanks · 3d ago
Medpace outlines 2025 revenue growth of up to 4.8% amid challenging business environment
Seeking Alpha · 3d ago
Harmonic Issues Weak Guidance, Joins Fluence Energy, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 3d ago
Analysts’ Top Healthcare Picks: Incyte (INCY), Medpace Holdings (MEDP)
TipRanks · 3d ago
Truist Financial Keeps Their Hold Rating on Medpace Holdings (MEDP)
TipRanks · 3d ago
Why Medpace (MEDP) Shares Are Trading Lower Today
Barchart · 3d ago
Closing Bell Movers: Lattice Semi up 13% on earnings
TipRanks · 4d ago
Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates
NASDAQ · 4d ago
Medpace Stock Falls On Q4 Earnings: The Details
Benzinga · 4d ago
Medpace Holdings Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 4d ago
*Medpace Holdings Sees 2025 EPS $11.93-EPS $12.69 >MEDP
Dow Jones · 4d ago
Medpace reports Q4 EPS $3.67, consensus $3.12
TipRanks · 4d ago
Medpace sees FY25 EPS $11.93-$12.69, consensus $12.29
TipRanks · 4d ago
*Medpace Holdings Sees 2025 Rev $2.11B-$2.210B >MEDP
Dow Jones · 4d ago
More
Webull provides a variety of real-time MEDP stock news. You can receive the latest news about Medpace Holdings through multiple platforms. This information may help you make smarter investment decisions.
About MEDP
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.